AGP Executive Report
Last update: 10 hours agoBiotech Funding: PureTech’s portfolio company Celea Therapeutics closed a $180M financing to start the Phase 3 SURPASS-IPF head-to-head trial of deupirfenidone (LYT-100) in early Q3 2026 for idiopathic pulmonary fibrosis. Cancer & Precision Medicine: Molecular Partners and Orano Med dosed the first patients in a US Phase 1/2a trial of DLL3-targeting Radio-DARPin MP0712 using lead-212 for small cell lung cancer and other neuroendocrine tumors. Kidney Disease Trial Results: Otsuka reported positive Phase 3 VISIONARY results for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy, showing statistically significant kidney function stabilization over two years. STEM Education & Research Capacity: Fifteen HBCUs launched the Association of HBCU Research Institutions (AHRI) at Howard University to compete for more federal research dollars. Local Science Spotlight: The National Geographic Museum of Exploration opened in Washington, D.C., with university researchers attending and connecting climate fieldwork to public exhibits. Public Health & Climate: Extreme heat warnings hit the Northeast and Midwest ahead of July 4, with cooling centers opening and health risks emphasized.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
